CorMedix Inc. (CRMD) Covered Calls
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions. Its flagship product, DefenCath, is an antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections in patients undergoing hemodialysis. The company also manages a diverse portfolio of anti-infective products and is expanding into pediatric and nutritional applications.
You can sell covered calls on CorMedix Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CRMD (prices last updated Fri 4:16 PM ET):
| CorMedix Inc. (CRMD) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 7.39 | +0.26 | 7.30 | 7.40 | 1.2M | 3.5 | 0.6 |
| Covered Calls For CorMedix Inc. (CRMD) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 7 | 0.70 | 6.70 | 4.5% | 56.6% | |
| Jun 18 | 7 | 0.90 | 6.50 | 7.7% | 44.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
CorMedix Inc. is a commercial-stage biopharmaceutical company dedicated to addressing significant unmet medical needs in the field of infectious disease and critical care. Based in Berkeley Heights, New Jersey, the company has transitioned from a development-focused entity into a diversified commercial operation. Its primary focus is the reduction of healthcare-associated infections, which represent a substantial burden on both patient outcomes and global healthcare systems.
Core Business and Products
The company's lead product is DefenCath® (taurolidine and heparin), a specialized catheter lock solution (CLS) approved by the FDA to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure receiving chronic hemodialysis. Following its 2025 acquisition of Melinta Therapeutics, CorMedix expanded its commercial portfolio to include several established anti-infective agents such as MINOCIN®, VABOMERE®, and ORBACTIV®. These products allow the company to provide comprehensive treatment and prevention solutions across various hospital and outpatient settings.
Competitive Landscape
The market for anti-infectives and infection prevention is highly competitive, featuring a mix of large pharmaceutical firms and specialized biotech companies. CorMedix competes based on the clinical efficacy of its proprietary formulations and its focus on specialized patient populations. Key publicly traded, optionable competitors include:
- ADMA Biologics: A biopharmaceutical company that develops and commercializes plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.
- Day One Biopharmaceuticals: A clinical-stage company focused on developing targeted therapies for patients of all ages with severe diseases, competing for institutional life-science capital.
- Relay Therapeutics: A precision medicine company that utilizes advanced computational platforms to design small molecule high-performance therapies.
- Esperion Therapeutics: While focused on lipid-lowering therapies, it is a similarly sized commercial-stage biopharma peer that competes for specialty pharmacy and hospital-channel attention.
- Merck & Co.: A global pharmaceutical giant that maintains a massive anti-infective and vaccine division, competing as both a potential partner and a market incumbent.
Strategic Outlook and Innovation
CorMedix is actively pursuing label expansions for DefenCath, with ongoing Phase III clinical trials aimed at securing approvals for use in pediatric hemodialysis and Total Parenteral Nutrition (TPN) patient populations. The company is also exploring the utility of its taurolidine-based technology in other medical devices and central venous catheter applications. A key strategic priority for 2026 is the successful navigation of reimbursement transitions for DefenCath to ensure broad patient access and long-term commercial viability.
The company maintains a growth-oriented capital allocation strategy, which includes investing in its R&D pipeline while evaluating further inorganic growth opportunities in the anti-infective space. By leveraging its established commercial infrastructure and deep expertise in infectious disease, CorMedix intends to drive sustainable revenue growth and achieve long-term profitability. The ultimate goal is to establish the company as a leader in the prevention of life-threatening infections, providing innovative tools that improve the standard of care for vulnerable patients.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | GLD covered calls | 1. | CMPX covered calls | |
| 2. | NVDA covered calls | 7. | HYG covered calls | 2. | FRMI covered calls | |
| 3. | TLT covered calls | 8. | QQQ covered calls | 3. | AXTI covered calls | |
| 4. | IBIT covered calls | 9. | KWEB covered calls | 4. | STNE covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | CLF covered calls | |
Want more examples? CRM Covered Calls | CRNC Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
